All In Biotech

Drug Trial Radar · NCT07175428

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,200

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Feb 9, 2027

Study completion Apr 21, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • REGN9933Drug

    Administered per the protocol

  • ApixabanDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of any bleedingTime frame: 12 weeks

Locations

91 sites in 4 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research

    Dothan, Alabama · Recruiting

  • Eastern Shore Research Institute

    Fairhope, Alabama · Recruiting

  • Valley Clinical Trials, Inc

    Covina, California · Recruiting

  • North Coast Cardiology

    Encinitas, California · Recruiting

  • Mission Cardiovascular Research Institute

    Fremont, California · Recruiting

  • National Institute of California Heart and Vein Specialists

    Huntington Beach, California · Recruiting

  • Profound Research LLC at Southern California Heart Specialists

    Pasadena, California · Recruiting

  • Empire Clinical Research

    Pomona, California · Recruiting

  • The Cardiovascular Center

    Redding, California · Recruiting

  • Northbay Clinical Research Center

    Santa Rosa, California · Recruiting

  • Cardiology Associates Medical Group

    Ventura, California · Recruiting

  • Interventional Cardiology Medical Group

    West Hills, California · Recruiting

  • Nouvelle Clinical Research LLC

    Cutler Bay, Florida · Recruiting

  • South Florida Research Organization LLC

    Medley, Florida · Recruiting

  • Inpatient Research Clinic LLC

    Miami Lakes, Florida · Recruiting

  • Cardiovascular Center of Sarasota Foundation for Research and Education

    Sarasota, Florida · Recruiting

  • Clinical Site Partners, LLC DBA Flourish Research

    Winter Park, Florida · Recruiting

  • Grady Health System

    Atlanta, Georgia · Recruiting

  • Health Sciences Research Building II

    Atlanta, Georgia · Withdrawn

  • NSC Research, Inc

    Johns Creek, Georgia · Recruiting

  • Indiana University

    Indianapolis, Indiana · Recruiting

  • Blue Coast Research Center, LLC

    Indianapolis, Indiana · Recruiting

  • Franciscan Physician Network, Indiana Heart Physicians

    Indianapolis, Indiana · Recruiting

  • Indiana Medical Research

    Merrillville, Indiana · Recruiting

  • Reid Physician Associates

    Richmond, Indiana · Recruiting

  • Monroe Research, LLC

    West Monroe, Louisiana · Recruiting

  • Anderson Medical Research

    Ft. Washington, Maryland · Recruiting

  • Beth Israel Lahey Health, Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts · Recruiting

  • Profound Research, Millennium Cardiology

    Farmington Hills, Michigan · Recruiting

  • AA Medical Research Center (MRC)

    Flint, Michigan · Recruiting

  • Fairview Health Services

    Maplewood, Minnesota · Recruiting

  • Moses Cone Hospital Operating Corporation dba Cone Health, Lebauer-Brodie Center for Cardiovascular Research

    Greensboro, North Carolina · Recruiting

  • K&R Research LLC

    Marion, Ohio · Recruiting

  • Advanced Medical Research

    Maumee, Ohio · Recruiting

  • Monument Health Clinical Research

    Rapid City, South Dakota · Recruiting

  • East Coast Institute for Research, Jefferson City

    Jefferson City, Tennessee · Recruiting

  • PharmaTex Research

    Amarillo, Texas · Recruiting

  • Complete Heart Care P.A.

    McKinney, Texas · Recruiting

  • Texas Institute of Cardiology PA

    McKinney, Texas · Recruiting

  • Synergy Group Medical, LLC

    Missouri City, Texas · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.